Trius Therapeutics Appoints Matthew Onaitis as General Counsel

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 3, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. where he led the legal, compliance and business development functions. Prior to his seven years at Somaxon, Mr. Onaitis served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.

Help employers find you! Check out all the jobs and post your resume.

Back to news